Epigenetic Strategies to Boost Cancer Immunotherapies.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

19 citing papers in PubMed.

1. Bromodomain and Extra-Terminal Proteins in Brain Physiology and Pathology: BET-ing on Epigenetic Regulation.Biomedicines · 2023
   Review
2. Decitabine increases neoantigen and cancer testis antigen expression to enhance T-cell-mediated toxicity against glioblastoma.Neuro-oncology · 2022
   Article
3. Current understanding of epigenetics role in melanoma treatment and resistance.Cancer cell international · 2022
   Review
4. Epi-immunotherapy for cancers: rationales of epi-drugs in combination with immunotherapy and advances in clinical trials.Cancer communications (London, England) · 2022
   Review
5. A Comprehensive Review of BET Protein Biochemistry, Physiology, and Pathological Roles.Frontiers in pharmacology · 2022
   Review
6. Abscopal Effect and Drug-Induced Xenogenization: A Strategic Alliance in Cancer Treatment?International journal of molecular sciences · 2021
   Review
7. The epigenetic immunomodulator, HBI-8000, enhances the response and reverses resistance to checkpoint inhibitors.BMC cancer · 2021
   Article
8. Epigenetic Regulation of Immunotherapy Response in Triple-Negative Breast Cancer.Cancers · 2021
   Review
9. HBI-8000, HUYABIO Lead Clinical Program, Is a Selective Histone Deacetylase Inhibitor With Therapeutic Benefits in Leukemia and in Solid Tumors.Frontiers in oncology · 2021
   Review
10. The therapeutic potential of targeting tryptophan catabolism in cancer.British journal of cancer · 2020
    Review
11. Pharmacokinetics-Driven Optimization of 7-Methylimidazo[1,5-ACS medicinal chemistry letters · 2019
    Article
12. Current Perspectives in Cancer Immunotherapy.Cancers · 2019
    Review
13. Breaking Therapy Resistance: An Update on Oncolytic Newcastle Disease Virus for Improvements of Cancer Therapy.Biomedicines · 2019
    Review
14. Exposure time versus cytotoxicity for anticancer agents.Cancer chemotherapy and pharmacology · 2019
    Article
15. Emerging roles of and therapeutic strategies targeting BRD4 in cancer.Cellular immunology · 2019
    Review
16. Impact of Epigenetic Regulation on Head and Neck Squamous Cell Carcinoma.Journal of dental research · 2019
    Article
17. Enhancing the Anticancer Efficacy of Immunotherapy through Combination with Histone Modification Inhibitors.Genes · 2018
    Review
18. Epigenetic Crosstalk between the Tumor Microenvironment and Ovarian Cancer Cells: A Therapeutic Road Less Traveled.Cancers · 2018
    Review
19. Patent trend and competitive analysis of cancer immunotherapy in the United States.Human vaccines & immunotherapeutics · 2017
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as